BNT326 — Investigational Agent
Antibody-Drug Conjugate · Phase 1/2 · BioNTech / MediLink Therapeutics
Mechanism of Action
An anti-HER3 antibody-drug conjugate delivering a topoisomerase I inhibitor payload via a tumor-microenvironment-activatable linker to HER3-expressing tumors, under study alone and combined with the PD-L1xVEGF bispecific BNT327.
Investigational Indications
- HER3-expressing non-small cell lung cancer
- Breast cancer
- Advanced solid tumors